The natriuretic peptides in cardiovascular medicine

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Within the last five years, assay systems for measurement of plasma levels of brain natriuretic peptide (BNP) have been approved as a diagnostic aid for heart failure (HF). Similarly, nesiritide, a recombinant form of human BNP, has been approved for the treatment of acutely decompensated HF. Both BNP as a diagnostic test and a therapeutic modality are rapidly becoming integrated into clinical practice. The purpose of this review is to provide a brief overview of the physiology of the natriuretic peptides relevant to their informed clinical use. The current literature regarding the utility of measuring BNP for the diagnosis and management of HF is reviewed and practical recommendations regarding the interpretation of BNP levels are offered. The clinical literature regarding the use of recombinant BNP for the treatment of HF is reviewed, underscoring current gaps in our knowledge regarding the indications for and benefits of this novel agent.

Original languageEnglish (US)
Pages (from-to)707-769
Number of pages63
JournalCurrent Problems in Cardiology
Volume29
Issue number12
DOIs
StatePublished - Dec 2004

Fingerprint

Natriuretic Peptides
Brain Natriuretic Peptide
Medicine
Heart Failure
Treatment Failure
Routine Diagnostic Tests

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The natriuretic peptides in cardiovascular medicine. / Munagala, Vijaya K.; Burnett, John C Jr.; Redfield, Margaret May.

In: Current Problems in Cardiology, Vol. 29, No. 12, 12.2004, p. 707-769.

Research output: Contribution to journalArticle

@article{c0ba233e9dcd4c9995c306e43b61f151,
title = "The natriuretic peptides in cardiovascular medicine",
abstract = "Within the last five years, assay systems for measurement of plasma levels of brain natriuretic peptide (BNP) have been approved as a diagnostic aid for heart failure (HF). Similarly, nesiritide, a recombinant form of human BNP, has been approved for the treatment of acutely decompensated HF. Both BNP as a diagnostic test and a therapeutic modality are rapidly becoming integrated into clinical practice. The purpose of this review is to provide a brief overview of the physiology of the natriuretic peptides relevant to their informed clinical use. The current literature regarding the utility of measuring BNP for the diagnosis and management of HF is reviewed and practical recommendations regarding the interpretation of BNP levels are offered. The clinical literature regarding the use of recombinant BNP for the treatment of HF is reviewed, underscoring current gaps in our knowledge regarding the indications for and benefits of this novel agent.",
author = "Munagala, {Vijaya K.} and Burnett, {John C Jr.} and Redfield, {Margaret May}",
year = "2004",
month = "12",
doi = "10.1016/j.cpcardiol.2004.07.002",
language = "English (US)",
volume = "29",
pages = "707--769",
journal = "Current Problems in Cardiology",
issn = "0146-2806",
publisher = "Mosby Inc.",
number = "12",

}

TY - JOUR

T1 - The natriuretic peptides in cardiovascular medicine

AU - Munagala, Vijaya K.

AU - Burnett, John C Jr.

AU - Redfield, Margaret May

PY - 2004/12

Y1 - 2004/12

N2 - Within the last five years, assay systems for measurement of plasma levels of brain natriuretic peptide (BNP) have been approved as a diagnostic aid for heart failure (HF). Similarly, nesiritide, a recombinant form of human BNP, has been approved for the treatment of acutely decompensated HF. Both BNP as a diagnostic test and a therapeutic modality are rapidly becoming integrated into clinical practice. The purpose of this review is to provide a brief overview of the physiology of the natriuretic peptides relevant to their informed clinical use. The current literature regarding the utility of measuring BNP for the diagnosis and management of HF is reviewed and practical recommendations regarding the interpretation of BNP levels are offered. The clinical literature regarding the use of recombinant BNP for the treatment of HF is reviewed, underscoring current gaps in our knowledge regarding the indications for and benefits of this novel agent.

AB - Within the last five years, assay systems for measurement of plasma levels of brain natriuretic peptide (BNP) have been approved as a diagnostic aid for heart failure (HF). Similarly, nesiritide, a recombinant form of human BNP, has been approved for the treatment of acutely decompensated HF. Both BNP as a diagnostic test and a therapeutic modality are rapidly becoming integrated into clinical practice. The purpose of this review is to provide a brief overview of the physiology of the natriuretic peptides relevant to their informed clinical use. The current literature regarding the utility of measuring BNP for the diagnosis and management of HF is reviewed and practical recommendations regarding the interpretation of BNP levels are offered. The clinical literature regarding the use of recombinant BNP for the treatment of HF is reviewed, underscoring current gaps in our knowledge regarding the indications for and benefits of this novel agent.

UR - http://www.scopus.com/inward/record.url?scp=8444220555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8444220555&partnerID=8YFLogxK

U2 - 10.1016/j.cpcardiol.2004.07.002

DO - 10.1016/j.cpcardiol.2004.07.002

M3 - Article

C2 - 15550914

AN - SCOPUS:8444220555

VL - 29

SP - 707

EP - 769

JO - Current Problems in Cardiology

JF - Current Problems in Cardiology

SN - 0146-2806

IS - 12

ER -